Germany's Bayer already partners with MIT and Harvard on oncology research, and now the partnership is being upgraded to include cardiovascular genomics and drug discovery. The expansion of the alliance into cardiovascular genomics will be about the search for genetic biomarkers of patient risk or suitability to particular drugs that treat cardiovascular conditions like heart disease.
At the American College of Cardiology annual meeting, researchers from the Cleveland Clinic and Duke University Medical Center determined that the level of the ST2 protein is a good predictor of adverse events and death in heart failure patients.
GE Healthcare announced that its diagnostic laboratory company, Clarient, will soon deploy Omnyx's proprietary software, as pathology pivots away from visual diagnosis and toward quantitative computer-based tools.
Amarantus BioSciences Holdings struck a deal with Anavex Life Sciences to provide biomarker test services for the company's Alzheimer's drug candidates, a major win for Amarantus as it looks to expand the reach of its blood diagnostic test.
Israel's Pocared Diagnostics announced that it has raised $15 million in milestone-based funding as it attempts to commercialize its culture-free, computer-based diagnostic platform for bacterial identification and another for analysis of biological particles.
Trovagene, developer of a urine-based cancer diagnostic, announced last week plans to sell 4,444,444 shares of common stock for $20 million. The San Diego-based company makes technology for detecting cell-free DNA and RNA resulting from diseased cell death in the urine of cancer patients.
Abbott Laboratories' diagnostics unit charted sizable gains in 2014, and the company is continuing its upward momentum in the new year with an exclusive licensing deal with the Institut Curie.
Researchers at Florida's Moffitt Cancer Center are gaining deeper insight into the biological processes going on inside a tumor in an effort to battle cancer more effectively. They've developed a new technique to analyze specific protein complexes in cancer specimens.
Investigators at Cold Spring Harbor Laboratory say they've identified a biomarker that can quickly highlight a potentially deadly mutation in p53, a natural tumor suppressor.
A new study presented at the Radiological Society of North America highlighted changes in brain connections that could be spotted in an MRI and may offer an imaging biomarker for early Alzheimer's.